Neratinib + Loperamide + Colestipol + Budesonide
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Stage HER2+ Breast Cancer
Conditions
Early Stage HER2+ Breast Cancer
Trial Timeline
Feb 1, 2015 → Apr 22, 2021
NCT ID
NCT02400476About Neratinib + Loperamide + Colestipol + Budesonide
Neratinib + Loperamide + Colestipol + Budesonide is a phase 2 stage product being developed by Puma Biotechnology for Early Stage HER2+ Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02400476. Target conditions include Early Stage HER2+ Breast Cancer.
What happened to similar drugs?
2 of 20 similar drugs in Early Stage HER2+ Breast Cancer were approved
Approved (2) Terminated (2) Active (17)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02400476 | Phase 2 | Completed |
Competing Products
20 competing products in Early Stage HER2+ Breast Cancer